Laura Panattoni, Ph.D.
Laura Panattoni, Ph.D., is a Research Economist at the Palo Alto Medical Foundation Research Institute (PAMFRI). Dr. Panattoni's research focuses on the evaluation of primary care redesign initiatives, developing new costing methodology, and patient and provider interaction with health information technology. She is currently leading a study of a new primary care based team model for treating patients with multiple chronic conditions and an activity-based costing of primary care transformation at PAMF, along with conducting studies assessing the impact of secure messaging and automatic lab ordering on service utilization.
Prior to joining PAMFRI in 2012, Dr. Panattoni was a Postdoctoral Fellow in Health Economics at the University of Auckland in New Zealand. There she led studies investigating the cost-effectiveness of genetic testing, estimating the demand for public versus private secondary care, and assessing the private market characteristics of specialist fees for low volume procedures. Her previous US-related research includes estimating the financial impact of “Paragraph IV” patent infringement decisions on brand drug pharmaceutical firms.
Dr. Panattoni holds a Doctorate and Master degree in Social Sciences (economics concentration) from the California Institute of Technology, and a BS degree in economics from Duke University.
She is also a recipient of the 2014 HMORN Early Career Investigator Award.
Tai-Seale, M., Wilson, C., Panattoni, L., Kohli, N., Stone, A., Hung, D., & Chung, C. “Leveraging Electronic Health Records to Develop Measurements for Processes of Care” Forthcoming in Health Services Research.
Panattoni, L., Brown, P., Te Ao, B., Webster, M., & Gladding, P. “Personalised Thienopyridine Therapy: the Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Treatment in Patients with Acute Coronary Syndromes” PharmacoEconomics 30(11): 1067-1084.
Panattoni, L. (2011) “The Effect of `Paragraph IV’ Decisions and Generic Entry before Patent Expiration on Brand Pharmaceutical Firms” The Journal of Health Economics 30(1): 126-145.
Panattoni, L., Brown, P., & Windsor, J. “Surgical Reimbursements and Relative Value Scales: Should We Rely on Market Competition?” Journal of Health Services Research and Policy 16(4): 203-210.
Panattoni, L., Vaithianathan, R., Ashton, T., & Lewis, G. “Predictive Risk Modeling in Health: Options for New Zealand and Australia” Australian Health Review 35(1): 45-51.
Gladding, P., Panattoni, L., Webster, M., Cho, L., & Ellis, S. “Clopidogrel Pharmacogenomics Next Steps: A Clinical Algorithm, Gene-Gene Interactions, and an Elusive Outcomes Trial” JACC: Cardiovascular Interventions 3(10): 995-1000.